Search trials



Primary RegistryProtocol numberPublic titleScientific titleType of studyRecruitment statusLast updated
LBCTR2021114915WA40404A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisA PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSISInterventionalPending05/11/2021
LBCTR2022034916AG348-C-020A Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease (SCD)A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell DiseaseInterventionalPending08/11/2021
LBCTR20220749784202-HEM-201A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of FT-4202 in Patients with Thalassemia or Sickle Cell DiseaseA Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of FT-4202 in Patients with Thalassemia or Sickle Cell DiseaseInterventionalPending18/01/2022
LBCTR2021104870SBS-2021-0102The effectiveness, mechanisms of change, and acceptability of Family Focused PsychoSocial Support for at-risk adolescents in LebanonThe effectiveness, mechanisms of change, and acceptability of Family Focused PsychoSocial Support for at-risk adolescents in LebanonInterventionalPending13/10/2021
LBCTR2022035012BIO-2021-0404Changes of Resting Metabolic Rate in University AthletesChanges of Resting Metabolic Rate in University AthletesInterventionalPending14/03/2022
LBCTR2022105089GBT021601-021A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell DiseaseA Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell DiseaseInterventionalPending07/07/2022
LBCTR2020063513GBT440-038Open-Label Extension of VoxelotorAn Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical TrialsInterventionalPending12/06/2020
LBCTR2022125202DCR-PHXC-204A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without DialysisA Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without DialysisInterventionalPending21/11/2022
LBCTR2023015204NCT05628389Phone Enabled Implementation of Cessation SupportPhone Enabled Implementation of Cessation SupportInterventionalPending21/11/2022
LBCTR2023015206R34MH121558Young adults as community mental health workers in humanitarian settingsYoung adults as community mental health workers in humanitarian settings: A pilot test of the mechanisms of effect on their own well-beingInterventionalPending24/11/2022
items per page61 - 70 of 176 items